메뉴 건너뛰기




Volumn 15, Issue 1, 2006, Pages 59-70

Tipranavir: A protease inhibitor for multi-drug resistant HIV-1

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral; Genotype; HIV drug resistance; HIV 1; Protease inhibitor; Tipranavir

Indexed keywords

AMPRENAVIR; ANTACID AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; ENFUVIRTIDE; ERGOT DERIVATIVE; ETHINYLESTRADIOL; GASTROINTESTINAL AGENT; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC SEDATIVE AGENT; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE;

EID: 29844453324     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.1.59     Document Type: Article
Times cited : (5)

References (41)
  • 1
    • 0032507027 scopus 로고    scopus 로고
    • Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
    • HOGG RS, HEATH KV, YIP B et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J. Am. Med. Assoc. (1998) 279(6):450-454.
    • (1998) J. Am. Med. Assoc. , vol.279 , Issue.6 , pp. 450-454
    • Hogg, R.S.1    Heath, K.V.2    Yip, B.3
  • 2
    • 2642709177 scopus 로고    scopus 로고
    • Declining morbidity and mortality among patients with advanced human immunodeficiency virus
    • infection HIV Outpatient Study Investigators
    • PALELLA FJ Jr, DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. (1998) 338(13):853-860.
    • (1998) N. Engl. J. Med. , vol.338 , Issue.13 , pp. 853-860
    • Palella Jr., F.J.1    Delaney, K.M.2    Moorman, A.C.3
  • 3
    • 3042726798 scopus 로고    scopus 로고
    • Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel
    • YENI PG, HAMMER SM, HIRSCH MS et al.: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. J. Am. Med. Assoc. (2004) 292(2):251-265.
    • (2004) J. Am. Med. Assoc. , vol.292 , Issue.2 , pp. 251-265
    • Yeni, P.G.1    Hammer, S.M.2    Hirsch, M.S.3
  • 4
    • 0033576816 scopus 로고    scopus 로고
    • Efavirenz plus zidovudine lamivudine efavirenz plus indinavir indinavir plus zidovudine lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team
    • STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. (1999) 341(25):1865-1873.
    • (1999) N. Engl. J. Med. , vol.341 , Issue.25 , pp. 1865-1873
    • Staszewski, S.1    Morales-ramirez, J.2    Tashima, K.T.3
  • 5
    • 0034604276 scopus 로고    scopus 로고
    • Adherence to protease inhibitor therapy outcomes in patients with HIV infection
    • PATERSON DL, SWINDELLS S, MOHR J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133(1):21-30.
    • (2000) Ann. Intern. Med. , vol.133 , Issue.1 , pp. 21-30
    • Paterson, D.L.1    Swindells, S.2    Mohr, J.3
  • 6
    • 17744418262 scopus 로고    scopus 로고
    • Predictors of virological success ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study
    • PAREDES R, MOCROFT A, KIRK O et al.: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch. Intern. Med. (2000) 160(8):1123-1132.
    • (2000) Arch. Intern. Med. , vol.160 , Issue.8 , pp. 1123-1132
    • Paredes, R.1    Mocroft, A.2    Kirk, O.3
  • 7
    • 0033550965 scopus 로고    scopus 로고
    • Clinical progression virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
    • LEDERGERBER B, EGGER M, OPRAVIL M et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 353(9156):863-868.
    • (1999) Lancet , vol.353 , Issue.9156 , pp. 863-868
    • Ledergerber, B.1    Egger, M.2    Opravil, M.3
  • 8
    • 9444228307 scopus 로고    scopus 로고
    • Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA study group
    • MOCROFT A, LEDERGERBER B, VIARD JP et al.: Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J. Infect. Dis. (2004) 190(11):1947-1956.
    • (2004) J. Infect. Dis. , vol.190 , Issue.11 , pp. 1947-1956
    • Mocroft, A.1    Ledergerber, B.2    Viard, J.P.3
  • 9
    • 20144386998 scopus 로고    scopus 로고
    • Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: Multicentre cohort study
    • SABIN CA, HILL T, LAMPE F et al.: Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. Br. Med. J. (2005) 330(7493):695.
    • (2005) Br. Med. J. , vol.330 , Issue.7493 , pp. 695
    • Sabin, C.A.1    Hill, T.2    Lampe, F.3
  • 10
    • 10044230450 scopus 로고    scopus 로고
    • Strategies for overcoming resistance in HIV- 1 infected patients receiving HAART
    • CLOTET B: Strategies for overcoming resistance in HIV- 1 infected patients receiving HAART. AIDS Rev. (2004) 6(3):123-130.
    • (2004) AIDS Rev. , vol.6 , Issue.3 , pp. 123-130
    • Clotet, B.1
  • 11
    • 0035808534 scopus 로고    scopus 로고
    • Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens
    • MONTANER JSG, HARRIGAN PR, JAHNKE N et al.: Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS (2001) 15(1):61-69.
    • (2001) AIDS , vol.15 , Issue.1 , pp. 61-69
    • Montaner, J.S.G.1    Harrigan, P.R.2    Jahnke, N.3
  • 12
    • 0037055027 scopus 로고    scopus 로고
    • Dual versus single protease inhibitor therapy following antiretroviral treatment failure
    • HAMMER SM, VAIDA F, BENNETT KK et al.: Dual versus single protease inhibitor therapy following antiretroviral treatment failure. J. Am. Med. Assoc. (2002) 288(2):169-180.
    • (2002) J. Am. Med. Assoc. , vol.288 , Issue.2 , pp. 169-180
    • Hammer, S.M.1    Vaida, F.2    Bennett, K.K.3
  • 13
    • 0033047131 scopus 로고    scopus 로고
    • Structure-based discovery of tipranavir disodium (PNU-140690E): A potent orally bioavailable nonpeptidic HIV protease inhibitor
    • THAISRIVONGS S, STROHBACH JW: Structure-based discovery of tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers (1999) 51(1):51-58.
    • (1999) Biopolymers , vol.51 , Issue.1 , pp. 51-58
    • Thaisrivongs, S.1    Strohbach, J.W.2
  • 14
    • 12944322516 scopus 로고    scopus 로고
    • Tipranavir (PNU-140690): A potent orally bioavailable nonpeptidic HIV protease inhibitor of the 56-dihydro-4-hydroxy-2-pyrone sulfonamide class
    • TURNER SR, STROHBACH JW, TOMMASI RA et al.: Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. (1998) 41(18):3467-3476.
    • (1998) J. Med. Chem. , vol.41 , Issue.18 , pp. 3467-3476
    • Turner, S.R.1    Strohbach, J.W.2    Tommasi, R.A.3
  • 15
    • 13844296701 scopus 로고    scopus 로고
    • Pharmacokinetic characterization of different dose combinations of coadministered tipranavir ritonavir in healthy volunteers
    • MacGREGOR TR, SABO JP, NORRIS SH et al.: Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin. Trials (2004) 5(6):371-382.
    • (2004) HIV Clin. Trials , vol.5 , Issue.6 , pp. 371-382
    • MacGregor, T.R.1    Sabo, J.P.2    Norris, S.H.3
  • 16
    • 1542409142 scopus 로고    scopus 로고
    • A 14-day dose-response study of the efficacy safety pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients
    • McCALLISTER S, VALDEZ H, CURRY K et al.: A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. (2004) 35(4):376-382.
    • (2004) J. Acquir. Immune Defic. Syndr. , vol.35 , Issue.4 , pp. 376-382
    • McCallister, S.1    Valdez, H.2    Curry, K.3
  • 17
    • 29844451824 scopus 로고    scopus 로고
    • Evaluation of the bioavailability of tipranavir/ritonavir (TPV/r) 500mg/200mg oral solution (OS): Comparison to TPV capsules the influence of food intake in healthy volunteers
    • Quebec Canada (April 28 - 30) (Abstract 42)
    • SABO JP, HUETTNER S, MacGREGOR T: Evaluation of the bioavailability of tipranavir/ritonavir (TPV/r) 500mg/200mg oral solution (OS): comparison to TPV capsules, and the influence of food intake in healthy volunteers. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada (April 28 - 30 2005) (Abstract 42).
    • (2005) 6th International Workshop on Clinical Pharmacology of HIV Therapy
    • Sabo, J.P.1    Huettner, S.2    MacGregor, T.3
  • 18
    • 0012877758 scopus 로고    scopus 로고
    • Correlation of viral load reduction plasma levels in multiple protease inhibitor experienced patients taking tipranavir/ritonavir in a Phase IIB trial: BI 1182.52
    • Boston USA (Abstract 528)
    • YENI P MacGREGOR T, GATHE J et al.: Correlation of viral load reduction and plasma levels in multiple protease inhibitor experienced patients taking tipranavir/ritonavir in a Phase IIB trial: BI 1182.52. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003) (Abstract 528).
    • (2003) 10th Conference on Retroviruses Opportunistic Infections
    • Yeni, P.1    MacGregor, T.2    Gathe, J.3
  • 19
    • 29844434313 scopus 로고    scopus 로고
    • Population pharmacokinetic assessment of systemic steady-state tipranavir concentrations for adults administered tipranavir/ritonavir 500/200 mg twice daily
    • Boston USA (February 22 - 25) (Abstract 654)
    • YONG CL, SABO JP, OKSALA C et al.: Population pharmacokinetic assessment of systemic steady-state tipranavir concentrations for adults administered tipranavir/ritonavir 500/200 mg twice daily. 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA (February 22 - 25 2005) (Abstract 654).
    • (2005) 12th Conference on Retroviruses Opportunistic Infections
    • Yong, C.L.1    Sabo, J.P.2    Oksala, C.3
  • 20
    • 29844451441 scopus 로고    scopus 로고
    • The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients
    • San Francisco USA (Abstract 81)
    • PHILLIPS L, BORIN M, HOPKINS NK, DAENZER CL, WANG Y: The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA (2000) (Abstract 81).
    • (2000) 7th Conference on Retroviruses Opportunistic Infections
    • Phillips, L.1    Borin, M.2    Hopkins, N.K.3    Daenzer, C.L.4    Wang, Y.5
  • 21
    • 11244292470 scopus 로고    scopus 로고
    • Pharmacokinetics safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV) amprenavir (APV) or lopinavir (LPV): Interim analysis of BI 1182.51
    • Rome Italy (April 1 - 3) (Session 5)
    • LEITH J, WALMSLEY S, KATLAMA C et al.: Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI 1182.51. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, Italy (April 1 - 3 2004) (Session 5).
    • (2004) 5th International Workshop on Clinical Pharmacology of HIV Therapy
    • Leith, J.1    Walmsley, S.2    Katlama, C.3
  • 22
    • 3543083046 scopus 로고    scopus 로고
    • The effect of tipranavir/ritonavir 500mg/200mg bid (TPV/r) on the pharmacokinetics of fluconazole in healthy volunteers
    • Rome Italy (April 1 - 3) (Abstract 4.8)
    • VAN HEESWIJK R, SABO JP, MacGREGOR T et al.: The effect of tipranavir/ritonavir 500mg/200mg bid (TPV/r) on the pharmacokinetics of fluconazole in healthy volunteers. 5th International Workshop on Clinical Pharmacology in HIV Therapy, Rome, Italy (April 1 - 3 2004) (Abstract 4.8).
    • (2004) 5th International Workshop on Clinical Pharmacology in HIV Therapy
    • Van Heeswijk, R.1    Sabo, J.P.2    MacGregor, T.3
  • 23
    • 3543149806 scopus 로고    scopus 로고
    • The pharmacokinetic interactions between tipranavir/ritonavir 500 mg/200 mg bid (TPV/r) atorvastatin antacid CYP3A4 in healthy volunteers
    • Rome Italy (April 1 - 3) (Abstract 5.2)
    • VAN HEESWIJK R, SABO JP COOPER C et al.: The pharmacokinetic interactions between tipranavir/ritonavir 500 mg/200 mg bid (TPV/r) and atorvastatin, antacid and CYP3A4 in healthy volunteers. 5th International Workshop on Clinical Pharmacology in HIV Therapy, Rome, Italy (April 1 - 3 2004) (Abstract 5.2).
    • (2004) 5th International Workshop on Clinical Pharmacology in HIV Therapy
    • Van Heeswijk, R.1    Sabo, J.P.2    Cooper, C.3
  • 24
    • 29844457606 scopus 로고    scopus 로고
    • The pharmacokinetics (PK) of single-dose steady-state tipranavir/ritonavir (TPV/r) 500mg/200mg in subjects with mild or moderate hepatic impairment
    • Quebec Canada (April 28 - 30) (Abstract 3.11)
    • COOPER C, VAN HEESWIJK R, BILODEAU M et al.: The pharmacokinetics (PK) of single-dose and steady-state tipranavir/ritonavir (TPV/r) 500mg/200mg in subjects with mild or moderate hepatic impairment. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada (April 28 - 30 2005) (Abstract 3.11).
    • (2005) 6th International Workshop on Clinical Pharmacology of HIV Therapy
    • Cooper, C.1    Van Heeswijk, R.2    Bilodeau, M.3
  • 25
    • 0033956430 scopus 로고    scopus 로고
    • In vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors
    • BACK NK, VAN WIJK A, REMMERSWAAL D et al.: In vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS (2000) 14(1):101-102.
    • (2000) AIDS , vol.14 , Issue.1 , pp. 101-102
    • Back, N.K.1    Van Wijk, A.2    Remmerswaal, D.3
  • 26
    • 1642363348 scopus 로고    scopus 로고
    • Analysis of protease inhibitor combinations in vitro: Activity of lopinavir amprenavir tipranavir against HIV type 1 wild-type drug-resistant isolates
    • BULGHERONI E, CITTERIO P, CROCE F et al.: Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. J. Antimicrob. Chemother. (2004) 53(3):464-468.
    • (2004) J. Antimicrob. Chemother. , vol.53 , Issue.3 , pp. 464-468
    • Bulgheroni, E.1    Citterio, P.2    Croce, F.3
  • 27
    • 0030671536 scopus 로고    scopus 로고
    • In vitro combination of PNU- 140690 a human immunodeficiency virus type 1 protease inhibitor with ritonavir against ritonavir-sensitive -resistant clinical isolates
    • CHONG KT, PAGANO PJ: In vitro combination of PNU- 140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob. Agents Chemother. (1997) 41(11):2367-2373.
    • (1997) Antimicrob. Agents Chemother. , vol.41 , Issue.11 , pp. 2367-2373
    • Chong, K.T.1    Pagano, P.J.2
  • 28
    • 0034623020 scopus 로고    scopus 로고
    • Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples
    • LARDER BA, HERTOGS K, BLOOR S et al.: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS (2000) 14(13):1943-1948.
    • (2000) AIDS , vol.14 , Issue.13 , pp. 1943-1948
    • Larder, B.A.1    Hertogs, K.2    Bloor, S.3
  • 29
    • 0035984802 scopus 로고    scopus 로고
    • In vitro antiviral interaction of lopinavir with other protease inhibitors
    • MOLLA A, MO H, VASAVANONDA S et al.: In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob. Agents Chemother. (2002) 46(7):2249-2253.
    • (2002) Antimicrob. Agents Chemother. , vol.46 , Issue.7 , pp. 2249-2253
    • Molla, A.1    Mo, H.2    Vasavanonda, S.3
  • 30
    • 0030895692 scopus 로고    scopus 로고
    • Antiviral activity of the dihydropyrone PNU-140690 a new nonpeptidic human immunodeficiency virus protease inhibitor
    • POPPE SM, SLADE DE, CHONG KT et al.: Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. (1997) 41(5):1058-1063.
    • (1997) Antimicrob. Agents Chemother. , vol.41 , Issue.5 , pp. 1058-1063
    • Poppe, S.M.1    Slade, D.E.2    Chong, K.T.3
  • 31
    • 0034053044 scopus 로고    scopus 로고
    • Susceptibility to PNU- 140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors
    • RUSCONI S, LA SETA CATAMANCIO S, CITTERIO P et al.: Susceptibility to PNU- 140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. (2000) 44(5):1328-1332.
    • (2000) Antimicrob. Agents Chemother. , vol.44 , Issue.5 , pp. 1328-1332
    • Rusconi, S.1    La Seta Catamancio, S.2    Citterio, P.3
  • 32
    • 0042450392 scopus 로고    scopus 로고
    • Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52
    • Boston USA (Abstract 179)
    • GATHE J, KOHLBRENNER VM, PIERONE G et al.: Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003) (Abstract 179).
    • (2003) 10th Conference on Retroviruses Opportunistic Infections
    • Gathe, J.1    Kohlbrenner, V.M.2    Pierone, G.3
  • 33
    • 20844442867 scopus 로고    scopus 로고
    • OTHERS: RESIST-1: A Phase III, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in an antiretroviral (ARV)-experienced patients: 24 week data
    • Washington, DC, USA (October 30 - November 2) (Abstract H- 1137a)
    • HICKS C, OTHERS: RESIST-1: a Phase III, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in an antiretroviral (ARV)-experienced patients: 24 week data. 44th Interscience Conference on Antimicrobial Agents of Chemotherapy (ICAAC), Washington, DC, USA (October 30 - November 2 2004) (Abstract H- 1137a).
    • (2004) 44th Interscience Conference on Antimicrobial Agents of Chemotherapy (ICAAC)
    • Hicks, C.1
  • 34
    • 21944436966 scopus 로고    scopus 로고
    • TEAM R-S: 24 week data from RESIST-2: Phase III study of the efficacy and safety of background therapy plus tipranavir/ritonavir (TPV/r) or optimized ritonavir-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV + patients
    • Glasgow, UK (November 14 - 18) (Abstract PL-14.3)
    • CAHN P, TEAM R-S: 24 week data from RESIST-2: Phase III study of the efficacy and safety of background therapy plus tipranavir/ritonavir (TPV/r) or optimized ritonavir-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV + patients. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK (November 14 - 18 2004) (Abstract PL-14.3).
    • (2004) 7th International Congress on Drug Therapy in HIV Infection
    • Cahn, P.1
  • 35
    • 20544455821 scopus 로고    scopus 로고
    • 24-week RESIST study analyses: The efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen
    • Boston USA (February 22 - 25) (Abstract 560)
    • COOPER D, HICKS C, CAHN P et al.: 24-week RESIST study analyses: the efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen. 12th Conference of Retroviruses and Opportunistic Infections, Boston, USA, (February 22 - 25 2005) (Abstract 560).
    • (2005) 12th Conference of Retroviruses Opportunistic Infections
    • Cooper, D.1    Hicks, C.2    Cahn, P.3
  • 36
    • 29844435158 scopus 로고    scopus 로고
    • Health-related quality of life with tipranavir in combination with an optimized background regimen in 2 randomized clinical trials
    • Boston USA (February 22 - 25) (Abstract 617)
    • WU A, HUANG IC, LOBO F, BERZON R: Health-related quality of life with tipranavir in combination with an optimized background regimen in 2 randomized clinical trials. 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA (February 22 - 25 2005) (Abstract 617).
    • (2005) 12th Conference on Retroviruses Opportunistic Infections
    • Wu, A.1    Huang, I.C.2    Lobo, F.3    Berzon, R.4
  • 37
    • 0041949773 scopus 로고    scopus 로고
    • Baseline phenotypic susceptibility to tipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52)
    • Boston USA (Abstract 596)
    • COOPER D, HALL D, JAYAWEERA D et al.: Baseline phenotypic susceptibility to tipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52). 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003) (Abstract 596).
    • (2003) 10th Conference on Retroviruses Opportunistic Infections
    • Cooper, D.1    Hall, D.2    Jayaweera, D.3
  • 38
    • 0038746305 scopus 로고    scopus 로고
    • Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/RTV) in multiple PI-failure patients (BI 1182.2)
    • Seattle USA (Abstract 562-T)
    • SCHWARTZ R, KAZANJIAN P, SLATER L et al.: Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/RTV) in multiple PI-failure patients (BI 1182.2). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA (2002) (Abstract 562-T).
    • (2002) 9th Conference on Retroviruses Opportunistic Infections
    • Schwartz, R.1    Kazanjian, P.2    Slater, L.3
  • 39
    • 21944441495 scopus 로고    scopus 로고
    • Expected tipranavir resistance in a group of 589 patients with previous exposure to protease inhibitors
    • Rome Italy (March 11 - 13) (Session 3)
    • MIRANDA AC, DUQUE LM, CARVALHO AP et al.: Expected tipranavir resistance in a group of 589 patients with previous exposure to protease inhibitors. 2nd European HIV Drug Resistance Workshop, Rome, Italy (March 11 - 13 2004) (Session 3).
    • (2004) 2nd European HIV Drug Resistance Workshop
    • Miranda, A.C.1    Duque, L.M.2    Carvalho, A.P.3
  • 40
    • 14344256850 scopus 로고    scopus 로고
    • Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: Implications for tipranavir use
    • GALLEGO O, DE MENDOZA C, CORRAL A, BARRIOS A, SORIANO V: Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use. AIDS Patient Care STDS (2005) 19(2):67-69.
    • (2005) AIDS Patient Care STDS , vol.19 , Issue.2 , pp. 67-69
    • Gallego, O.1    De Mendoza, C.2    Corral, A.3    Barrios, A.4    Soriano, V.5
  • 41
    • 20844435865 scopus 로고    scopus 로고
    • Effect of baseline genotype on response to tipranavir/ritonavir (TPV/r) compared with standard-of-care comparator (CPI/r) in treatment-experienced patients: The Phase III RESIST-1 -2 trials
    • Boston USA (February 22 - 25) (Abstract 104)
    • SCHAPIRO JM, CAHN P TROTTIER B et al.: Effect of baseline genotype on response to tipranavir/ritonavir (TPV/r) compared with standard-of-care comparator (CPI/r) in treatment-experienced patients: the Phase III RESIST-1 and -2 trials. 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA (February 22 - 25 2005) (Abstract 104).
    • (2005) 12th Conference on Retroviruses Opportunistic Infections
    • Schapiro, J.M.1    Cahn, P.2    Trottier, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.